Article info

Download PDFPDF
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Authors

  1. Address correspondence and reprint requests to: Martine J. Piccart, MD, Jules Bordet Institute, Chemotherapy Unit, Rue Heger-Bordet, 1, 1000 Brussels, Belgium. Email: martine.piccart{at}bordet.be

Citation

Piccart MJ, Bertelsen K, Stuart G, et al
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Publication history

  • First published October 1, 2003.
Online issue publication 
October 01, 2003

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.